|
Vasopressin
drug data and news
Vasopressin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Vasopressin
|
| Brand Names/Synonyms |
Argiprestocin; Vasopressin; Arginine oxytocin; Pitressin tannate; Arginine vasotocin; Vasotocin; Vasopressin, isoleucyl; 3-Isoleucyl vasopressin; Vasopressin, non-mammalian; Pitressin; Pressyn |
| Indication |
Enuresis;Polyuria;Diabetes insipidus;Polydipsia;Oesophageal varices with bleeding |
|
Sponsored links
|
|
Description |
Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation |
| Pharmacology |
Vasopressin is an antidiuretic hormone indicated for the prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules. It has less effect on the smooth musculature of the large veins. Vasopressin may also be used to control bleeding in some forms of von Willebrand disease and to treat extreme cases of bed wetting in children. It may also play a role in memory formation although the mechanism is unknown. |
| Mechanism Of Action |
Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which controls free water reabsorption in the renal medullar. The binding of vasopressin to the V2 receptor activates adenylate cyclase which causes the release of aquaporin 2 channels into the cells lining the renal medullar duct. This allows water to be reabsorbed down an osmotic gradient so the urine is more concentrated. |
Vasopressin News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
LIQUID |
| Drug_Category |
Antidiuretics; Vasoconstrictor Agents; Pituitary (68:28.00); ATC:H01BA01 |
| Absorption |
Not Available |
| Interactions |
Interactions for Vasopressin:
1) The following drugs may potentiate the antidiuretic effect of vasopressin when used concurrently: carbamazepine; chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants.
2) The following drugs may decrease the antidiuretic effect of vasopressin when used concurrently: demeclocyline; norepinephrine; lithium; heparin, alcohol.
3) Ganglionic blocking agents may produce a marked increase in sensitivity to the pressor effects of vasopressin.
|
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
1-[[19-amino-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-13-(1-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-4-yl]carbonyl]-N-[1-(carbamoylmethylcarbamoyl)-4-guanidino-butyl]-pyrrolidine-2-carboxamide |
| Chemical Formula |
C43H67N15O12S2 |
| |
